These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 22766537)

  • 1. Estimating quality-adjusted life years from patient-reported visual functioning.
    Browne C; Brazier J; Carlton J; Alavi Y; Jofre-Bonet M
    Eye (Lond); 2012 Oct; 26(10):1295-301. PubMed ID: 22766537
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comparison of the sensitivity of EQ-5D, SF-6D and TTO utility values to changes in vision and perceived visual function in patients with primary open-angle glaucoma.
    Bozzani FM; Alavi Y; Jofre-Bonet M; Kuper H
    BMC Ophthalmol; 2012 Aug; 12():43. PubMed ID: 22909264
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Using the Multiple Sclerosis Impact Scale to estimate health state utility values: mapping from the MSIS-29, version 2, to the EQ-5D and the SF-6D.
    Hawton A; Green C; Telford C; Zajicek J; Wright D
    Value Health; 2012 Dec; 15(8):1084-91. PubMed ID: 23244811
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mapping the 25-item National Eye Institute Visual Functioning Questionnaire (NEI VFQ-25) to EQ-5D utility scores.
    Kay S; Ferreira A
    Ophthalmic Epidemiol; 2014 Apr; 21(2):66-78. PubMed ID: 24568628
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mapping QLQ-C30 Onto EQ-5D-5L and SF-6D-V2 in Patients With Colorectal and Breast Cancer From a Developing Country.
    Yousefi M; Nahvijou A; Sari AA; Ameri H
    Value Health Reg Issues; 2021 May; 24():57-66. PubMed ID: 33508752
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of vision-related quality of life in primary open-angle glaucoma and dry-type age-related macular degeneration.
    Karadeniz Ugurlu S; Kocakaya Altundal AE; Altin Ekin M
    Eye (Lond); 2017 Mar; 31(3):395-405. PubMed ID: 27813519
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mapping the cancer-specific EORTC QLQ-C30 to the preference-based EQ-5D, SF-6D, and 15D instruments.
    Kontodimopoulos N; Aletras VH; Paliouras D; Niakas D
    Value Health; 2009; 12(8):1151-7. PubMed ID: 19558372
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mapping health assessment questionnaire disability index (HAQ-DI) score, pain visual analog scale (VAS), and disease activity score in 28 joints (DAS28) onto the EuroQol-5D (EQ-5D) utility score with the KORean Observational study Network for Arthritis (KORONA) registry data.
    Kim HL; Kim D; Jang EJ; Lee MY; Song HJ; Park SY; Cho SK; Sung YK; Choi CB; Won S; Bang SY; Cha HS; Choe JY; Chung WT; Hong SJ; Jun JB; Kim J; Kim SK; Kim TH; Kim TJ; Koh E; Lee H; Lee HS; Lee J; Lee SS; Lee SW; Park SH; Shim SC; Yoo DH; Yoon BY; Bae SC; Lee EK
    Rheumatol Int; 2016 Apr; 36(4):505-13. PubMed ID: 26849891
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Measuring Contrast Sensitivity in Specific Areas of Vision - A Meaningful Way to Assess Quality of Life and Ability to Perform Daily Activities in Glaucoma.
    Eshraghi H; Sanvicente CT; Gogte P; Waisbourd M; Lee D; Manzi RRS; Leiby BE; Richman J; Wizov SS; Spaeth GL
    Ophthalmic Epidemiol; 2019 Oct; 26(5):301-310. PubMed ID: 31116620
    [No Abstract]   [Full Text] [Related]  

  • 10. Relationships Between Measures of the Ability to Perform Vision-Related Activities, Vision-Related Quality of Life, and Clinical Findings in Patients With Glaucoma.
    Ekici F; Loh R; Waisbourd M; Sun Y; Martinez P; Nayak N; Wizov SS; Hegarty S; Hark LA; Spaeth GL
    JAMA Ophthalmol; 2015 Dec; 133(12):1377-85. PubMed ID: 26425961
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mapping utility scores from a disease-specific quality-of-life measure in bariatric surgery patients.
    Sauerland S; Weiner S; Dolezalova K; Angrisani L; Noguera CM; García-Caballero M; Rupprecht F; Immenroth M
    Value Health; 2009; 12(2):364-70. PubMed ID: 20667063
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of visual field loss on health-related quality of life in glaucoma: the Los Angeles Latino Eye Study.
    McKean-Cowdin R; Wang Y; Wu J; Azen SP; Varma R;
    Ophthalmology; 2008 Jun; 115(6):941-948.e1. PubMed ID: 17997485
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mapping the cancer-specific QLQ-C30 onto the generic EQ-5D-5L and SF-6D in colorectal cancer patients.
    Ameri H; Yousefi M; Yaseri M; Nahvijou A; Arab M; Akbari Sari A
    Expert Rev Pharmacoecon Outcomes Res; 2019 Feb; 19(1):89-96. PubMed ID: 30173585
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predicting EQ-5D utility scores from the 25-item National Eye Institute Vision Function Questionnaire (NEI-VFQ 25) in patients with age-related macular degeneration.
    Payakachat N; Summers KH; Pleil AM; Murawski MM; Thomas J; Jennings K; Anderson JG
    Qual Life Res; 2009 Sep; 18(7):801-13. PubMed ID: 19543808
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of the relationship between quality of vision and the visual function index in Japanese glaucoma patients.
    Sawada H; Fukuchi T; Abe H
    Graefes Arch Clin Exp Ophthalmol; 2011 Nov; 249(11):1721-7. PubMed ID: 21858466
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Visual impairment and vision-related quality of life in the Early Manifest Glaucoma Trial after 20 years of follow-up.
    Peters D; Heijl A; Brenner L; Bengtsson B
    Acta Ophthalmol; 2015 Dec; 93(8):745-52. PubMed ID: 26382936
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mapping the Positive and Negative Syndrome Scale scores to EQ-5D-5L and SF-6D utility scores in patients with schizophrenia.
    Abdin E; Chong SA; Seow E; Verma S; Tan KB; Subramaniam M
    Qual Life Res; 2019 Jan; 28(1):177-186. PubMed ID: 30382480
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mapping the Chinese Version of the EORTC QLQ-BR53 Onto the EQ-5D-5L and SF-6D Utility Scores.
    Liu T; Li S; Wang M; Sun Q; Chen G
    Patient; 2020 Oct; 13(5):537-555. PubMed ID: 32382953
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mapping ALSFRS-R and ALSUI to EQ-5D in Patients with Motor Neuron Disease.
    Moore A; Young CA; Hughes DA
    Value Health; 2018 Nov; 21(11):1322-1329. PubMed ID: 30442280
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mapping analyses to estimate EQ-5D utilities and responses based on Oxford Knee Score.
    Dakin H; Gray A; Murray D
    Qual Life Res; 2013 Apr; 22(3):683-94. PubMed ID: 22555470
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.